|Bid||7.00 x 800|
|Ask||8.14 x 3100|
|Day's Range||8.08 - 8.73|
|52 Week Range||8.08 - 47.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 09, 2022 - Feb 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||42.00|
Subscribe to Yahoo Finance Plus to view Fair Value for ALVRLearn more
WALTHAM, Mass., January 05, 2022--AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus specific T cell (VST) therapy, posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of adenovirus (AdV) infection following allogeneic hematopoietic stem cell transplant (allo-HCT). The designation is based on positive results from the Phas
WALTHAM, Mass., January 03, 2022--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4:30 p.m. ET.
WALTHAM, Mass., December 16, 2021--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition.